This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

JDRF's "Kids For A Cure" Are Living Proof That A Cure For Type 1 Diabetes Is Within Reach

Since its founding in 1970 (1974 in Canada), JDRF has awarded more than $1.6 billion (U.S.) to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. More than 80 per cent of JDRF's expenditures directly support research and research-related education. For more information, please visit .

About JDRF Canadian Clinical Trial Network JDRF CCTN is supported by the Government of Canada, which committed $20 million through the Federal Economic Development Agency for Southern Ontario's Southern Ontario Development Program in 2009, and JDRF, which provided an additional $13.9 million. The $33.9 million investment is helping to bring new technologies and treatments to the marketplace and ensure that Canadians living with T1D and its complications are among the first to benefit from the latest research.

JDRF CCTN is a groundbreaking effort to accelerate solutions for the management, care, and cure of T1D. JDRF CCTN is currently developing a broad range of high-profile clinical trials in association with leading diabetes researchers at partner universities and medical centres in southern Ontario. By enhancing the existing clinical trial infrastructure in the province and providing high-profile training opportunities for seasoned and junior investigators alike, JDRF CCTN is positioning southern Ontario as an international hub for diabetes translational research, innovation, and commercialization of new therapeutics and enabling technologies. For more information, please visit .

_________________________________ i Juvenile Diabetes Research Foundation. Type 1 Fact Sheet. Accessed April 2012. iiJuvenile Diabetes Research Foundation, Fundraising Guide,$cms$/102/1411.pdf.Accessed April 2012. iiiSick Kids Hospital, New Study to Explore Risk Factors for Type 1 Diabetes, 2012.

JDRF 2012 National Kids for a Cure Co-Chairs

Megan Beamish   Megan Beamish is 14 years old from Halifax, Nova Scotia and she suffers from type 1 diabetes (T1D). Megan was diagnosed with T1D when she was 10 years old. Megan and her family have participated in the TELUS Walk to Cure Diabetes in Halifax three times and entered a team in the Ride for Diabetes Research once. Megan has fundraised nearly $10,000 for diabetes research. Her father is the volunteer chair of the Halifax chapter and the family actively promotes JDRF at malls, grocery stores and the Halifax waterfront. Last Christmas Megan's family entered a float into their local Christmas parade. Megan is a straight A student in grade nine who loves track & field with her specialties being high jump, long jump, triple jump and the 100 meter dash. Megan would like to be a Canadian Olympian or a Pediatric Endocrinologist when she is older. Video links: Megan's winning video for the JDRF Youth Video Contest: Michael Thornton   Michael Thornton is 12 years old from Toronto, Ontario and he suffers from type 1 diabetes (T1D).  Michael was diagnosed with T1D when he was 6 years old and he uses an insulin pump to manage his diabetes. Michael is an elite two sport athlete (soccer and track & field) who represented Canada in Switzerland at the Junior World Diabetes Cup. This young elite athlete is also a philanthropist who has organized major fundraisers that have included bringing members of the Toronto Raptors and the Toronto FC to his school for his annual "Haunted Graveyard" fundraising event. He also participates in the TELUS Walk to Cure Diabetes and other JDRF events. Michael is not only an exceptional athlete but an outgoing advocate for JDRF. He has made connections with MPs, the media and the public in an attempt to raise awareness about diabetes and to one day be part of finding a cure. Video links: Michael in England: Michael in Trial at A.S. Roma: Michael in Netherlands:


Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,837.84 +25.65 0.14%
S&P 500 2,087.19 -1.95 -0.09%
NASDAQ 5,104.0630 +1.2550 0.02%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs